380 related articles for article (PubMed ID: 23296045)
1. Apelin in epiretinal fibrovascular membranes of patients with retinopathy of prematurity and the changes after intravitreal bevacizumab.
Zhang Y; Jiang YR; Lu Q; Yin H; Tao Y
Retina; 2013 Mar; 33(3):613-20. PubMed ID: 23296045
[TBL] [Abstract][Full Text] [Related]
2. Vitreous and plasma concentrations of apelin and vascular endothelial growth factor after intravitreal bevacizumab in eyes with proliferative diabetic retinopathy.
Qian J; Lu Q; Tao Y; Jiang YR
Retina; 2011 Jan; 31(1):161-8. PubMed ID: 20890241
[TBL] [Abstract][Full Text] [Related]
3. Apelin in plasma and vitreous and in fibrovascular retinal membranes of patients with proliferative diabetic retinopathy.
Tao Y; Lu Q; Jiang YR; Qian J; Wang JY; Gao L; Jonas JB
Invest Ophthalmol Vis Sci; 2010 Aug; 51(8):4237-42. PubMed ID: 20220056
[TBL] [Abstract][Full Text] [Related]
4. An updated study of the use of bevacizumab in the treatment of patients with prethreshold retinopathy of prematurity in taiwan.
Wu WC; Kuo HK; Yeh PT; Yang CM; Lai CC; Chen SN
Am J Ophthalmol; 2013 Jan; 155(1):150-158.e1. PubMed ID: 22967867
[TBL] [Abstract][Full Text] [Related]
5. Serum levels of vascular endothelial growth factor and related factors after intravitreous bevacizumab injection for retinopathy of prematurity.
Wu WC; Lien R; Liao PJ; Wang NK; Chen YP; Chao AN; Chen KJ; Chen TL; Hwang YS; Lai CC
JAMA Ophthalmol; 2015 Apr; 133(4):391-7. PubMed ID: 25569026
[TBL] [Abstract][Full Text] [Related]
6. Preoperative intravitreal bevacizumab use as an adjuvant to diabetic vitrectomy: histopathologic findings and clinical implications.
El-Sabagh HA; Abdelghaffar W; Labib AM; Mateo C; Hashem TM; Al-Tamimi DM; Selim AA
Ophthalmology; 2011 Apr; 118(4):636-41. PubMed ID: 21055812
[TBL] [Abstract][Full Text] [Related]
7. Apelin in epiretinal membranes of patients with proliferative diabetic retinopathy.
Lu Q; Ma Y; Xu YS; Jiang YR
Mol Vis; 2014; 20():1122-31. PubMed ID: 25324682
[TBL] [Abstract][Full Text] [Related]
8. Effects and complications of bevacizumab use in patients with retinopathy of prematurity: a multicenter study in taiwan.
Wu WC; Yeh PT; Chen SN; Yang CM; Lai CC; Kuo HK
Ophthalmology; 2011 Jan; 118(1):176-83. PubMed ID: 20673589
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of neovascularization and expression shift of pro-/anti-angiogenic vascular endothelial growth factor isoforms after intravitreal bevacizumab injection in oxygen-induced-retinopathy mouse model.
Shi X; Zhao M; Xie WK; Liang JH; Miao YF; DU W; Li XX
Chin Med J (Engl); 2013 Jan; 126(2):345-52. PubMed ID: 23324288
[TBL] [Abstract][Full Text] [Related]
10. Role of the adrenergic system in a mouse model of oxygen-induced retinopathy: antiangiogenic effects of beta-adrenoreceptor blockade.
Ristori C; Filippi L; Dal Monte M; Martini D; Cammalleri M; Fortunato P; la Marca G; Fiorini P; Bagnoli P
Invest Ophthalmol Vis Sci; 2011 Jan; 52(1):155-70. PubMed ID: 20739470
[TBL] [Abstract][Full Text] [Related]
11. Laser-induced choroidal neovascularization in mice attenuated by deficiency in the apelin-APJ system.
Hara C; Kasai A; Gomi F; Satooka T; Sakimoto S; Nakai K; Yoshioka Y; Yamamuro A; Maeda S; Nishida K
Invest Ophthalmol Vis Sci; 2013 Jun; 54(6):4321-9. PubMed ID: 23722395
[TBL] [Abstract][Full Text] [Related]
12. Vitreous levels of erythropoietin and vascular endothelial growth factor in eyes with retinopathy of prematurity.
Sato T; Kusaka S; Shimojo H; Fujikado T
Ophthalmology; 2009 Sep; 116(9):1599-603. PubMed ID: 19371954
[TBL] [Abstract][Full Text] [Related]
13. Intravitreal bevacizumab for retinopathy of prematurity: refractive error results.
Harder BC; Schlichtenbrede FC; von Baltz S; Jendritza W; Jendritza B; Jonas JB
Am J Ophthalmol; 2013 Jun; 155(6):1119-1124.e1. PubMed ID: 23490192
[TBL] [Abstract][Full Text] [Related]
14. Concentration of vascular endothelial growth factor in aqueous humor of eyes with advanced retinopathy of prematurity before and after intravitreal injection of bevacizumab.
Nonobe NI; Kachi S; Kondo M; Takai Y; Takemoto K; Nakayama A; Hayakawa M; Terasaki H
Retina; 2009 May; 29(5):579-85. PubMed ID: 19430279
[TBL] [Abstract][Full Text] [Related]
15. Structural consequences after intravitreal bevacizumab injection without increasing apoptotic cell death in a retinopathy of prematurity mouse model.
Akkoyun I; Karabay G; Haberal N; Dagdeviren A; Yilmaz G; Oto S; Erkanli L; Akova YA
Acta Ophthalmol; 2012 Sep; 90(6):564-70. PubMed ID: 20698831
[TBL] [Abstract][Full Text] [Related]
16. Colocalization of Tie2, angiopoietin 2 and vascular endothelial growth factor in fibrovascular membrane from patients with retinopathy of prematurity.
Umeda N; Ozaki H; Hayashi H; Miyajima-Uchida H; Oshima K
Ophthalmic Res; 2003; 35(4):217-23. PubMed ID: 12815197
[TBL] [Abstract][Full Text] [Related]
17. Vitreous levels of angiopoietin-1 and angiopoietin-2 in eyes with retinopathy of prematurity.
Sato T; Shima C; Kusaka S
Am J Ophthalmol; 2011 Feb; 151(2):353-7.e1. PubMed ID: 21168819
[TBL] [Abstract][Full Text] [Related]
18. Early vitreoretinal surgery on vascularly active stage 4 retinopathy of prematurity through the preoperative intravitreal bevacizumab injection.
Xu Y; Zhang Q; Kang X; Zhu Y; Li J; Chen Y; Zhao P
Acta Ophthalmol; 2013 Jun; 91(4):e304-10. PubMed ID: 23647944
[TBL] [Abstract][Full Text] [Related]
19. SB-267268, a nonpeptidic antagonist of alpha(v)beta3 and alpha(v)beta5 integrins, reduces angiogenesis and VEGF expression in a mouse model of retinopathy of prematurity.
Wilkinson-Berka JL; Jones D; Taylor G; Jaworski K; Kelly DJ; Ludbrook SB; Willette RN; Kumar S; Gilbert RE
Invest Ophthalmol Vis Sci; 2006 Apr; 47(4):1600-5. PubMed ID: 16565398
[TBL] [Abstract][Full Text] [Related]
20. Outcomes after Intravitreal Bevacizumab versus Laser Photocoagulation for Retinopathy of Prematurity: A 5-Year Retrospective Analysis.
Hwang CK; Hubbard GB; Hutchinson AK; Lambert SR
Ophthalmology; 2015 May; 122(5):1008-15. PubMed ID: 25687024
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
